2021 Revenues ($USD) : $21,651,820,000
2021 Revenues (foreign currencies) : €18,349,000,000
2021 R&D spend : $3,704,020,000
2021 Number of Employees : 39,931
Fiscal Year End : 12/31/2021
Leader : CEO Werner Baumann

Bayer's pharmaceutical division saw strong growth in 2021. The macular degeneration drug Eylea (aflibercept) and the blood thinner Xarelto (rivaroxaban) helped boost revenue. The company also won regulatory approvals for the prostate cancer therapy Nubeqa (darolutamide), heart failure drug Verquvo (vericiguat), and Kerendia (finerenone) for chronic kidney disease associated with type 2 diabetes. To fuel future growth, Bayer is banking on cell and gene therapy. In late 2020, the company acquired Asklepios BioPharmaceutic, an adeno-associated virus gene therapy company. In 2022, the company announced its plans to invest €2 billion over the next three years to improve its manufacturing and supply chain facilities. —BB